Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Research & Development (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Research & Development for 2 consecutive years, with $697723.0 as the latest value for Q4 2025.

  • Quarterly Research & Development fell 59.83% to $697723.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $9.0 million for FY2025, 4.38% down from the prior year.
  • Research & Development for Q4 2025 was $697723.0 at Neuphoria Therapeutics, down from $3.8 million in the prior quarter.
  • The five-year high for Research & Development was $3.8 million in Q3 2025, with the low at $697723.0 in Q4 2025.